Shares of Lantheus Holdings, Inc. (LNTH) rose 5% after hours on Friday after the company announced that the U.S. Food and Drug Administration has approved its PYLARIFY TruVu injection.

Add Asianet Newsable as a Preferred Source

The injection is indicated for imaging certain lesions in men with prostate cancer.

It is now expected to be commercially available in the fourth quarter of 2026.

Get updates to this developing story directly on Stocktwits.<